VIA
AMLX icon

Virtus Investment Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Virtus Investment Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Buy
22,426
+1,611
+8% +$24.9K 0.09% 274
2026
Q1 		$289K Buy
20,815
+508
+3% +$7.15K 0.08% 284
2025
Q4 		$245K Buy
+20,307
New +$276K 0.07% 336

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Virtus Investment Advisers's AMLX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Amylyx Pharmaceuticals (AMLX) stake by 7.7% in Q2 2026, buying an estimated $24.9K and bringing the position to 22,426 shares worth $403K. The position accounts for 0.09% of the portfolio, ranked #274.

Virtus Investment Advisers first reported a position in AMLX in Q4 2025 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Virtus Investment Advisers held 22,426 shares of Amylyx Pharmaceuticals worth $403K as of Q2 2026.
  • Virtus Investment Advisers bought 1,611 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $24.9K.
  • Amylyx Pharmaceuticals made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #274 holding.
  • Virtus Investment Advisers first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.